Electrodiagnosis

CardioComm Solutions Completes Issuance of Shares for Debt

Retrieved on: 
Wednesday, May 12, 2021
Medicine, Branches of biology, Clinical medicine, Cardiac electrophysiology, Electrocardiography, Electrodiagnosis, Electrophysiology, Science and technology in the Netherlands, Debt settlement, ISO 13485, D. Medical Industries, ERT

b'Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it has completed its previously announced issuance of shares for debt (see the Company\'s press releases dated April 27, 2021 and April 8, 2021 for further details).\nUnder debt settlement agreements, the Company has issued an aggregate of 3,353,644 common shares of the Company ("Shares") to directors, employees and consultants of the Company to settle debt for services provided to the Company.

Key Points: 
  • b'Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it has completed its previously announced issuance of shares for debt (see the Company\'s press releases dated April 27, 2021 and April 8, 2021 for further details).\nUnder debt settlement agreements, the Company has issued an aggregate of 3,353,644 common shares of the Company ("Shares") to directors, employees and consultants of the Company to settle debt for services provided to the Company.
  • Products are sold worldwide through a combination of an external distribution network and a North American-based sales team.
  • CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).\nFOR FURTHER INFORMATION PLEASE CONTACT:\nThis release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items.
  • Such statements and information reflect management\'s current beliefs and are based on information currently available to management.

Assure to Attend Investor Conferences in May 2021

Retrieved on: 
Wednesday, May 12, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, XC2, OTC Markets Group, Branches of biology

b'DENVER, May 12, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences in May 2021:\nBenzinga Global Small Cap Conference May 13-14, 2021.

Key Points: 
  • b'DENVER, May 12, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences in May 2021:\nBenzinga Global Small Cap Conference May 13-14, 2021.
  • Assure\xe2\x80\x99s executive chairman and CEO John Farlinger is scheduled to present on May 13th at 5:05 p.m.
  • Register for a free spectator pass for this event here: https://www.benzinga.com/events/small-cap/global/\nSidoti\xe2\x80\x99s Virtual Microcap Investor Conference May 19-20, 2021.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission\xe2\x80\x99s Gold Seal of Approval\xc2\xae.

Assure Holdings Sets First Quarter 2021 Conference Call for Friday, May 14, 2021, at 12:00 p.m. ET

Retrieved on: 
Tuesday, May 11, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, XE-class submarine, Branches of biology

The Company will report its financial results in a press release prior to the conference call.\nPlease call the conference telephone number 5-10 minutes prior to the start time.

Key Points: 
  • The Company will report its financial results in a press release prior to the conference call.\nPlease call the conference telephone number 5-10 minutes prior to the start time.
  • Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commission\xe2\x80\x99s Gold Seal of Approval\xc2\xae.
  • For more information, visit the Company\xe2\x80\x99s website at www.assureneuromonitoring.com .\nThis news release may contain \xe2\x80\x9cforward-looking statements\xe2\x80\x9d within the meaning of applicable securities laws.

Assure Holdings Enters into In-Network Agreement with Aetna Colorado

Retrieved on: 
Wednesday, April 28, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, XE-class submarine, Branches of biology

b'DENVER, April 28, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (\xe2\x80\x9cIONM\xe2\x80\x9d), is pleased to announce that it has signed an agreement (the \xe2\x80\x9cAgreement\xe2\x80\x9d) with Aetna Colorado (\xe2\x80\x9cAetna\xe2\x80\x9d).

Key Points: 
  • b'DENVER, April 28, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (\xe2\x80\x9cIONM\xe2\x80\x9d), is pleased to announce that it has signed an agreement (the \xe2\x80\x9cAgreement\xe2\x80\x9d) with Aetna Colorado (\xe2\x80\x9cAetna\xe2\x80\x9d).
  • \xe2\x80\x9cExecuting this Agreement is another important step forward as Assure further develops an in-network revenue stream.\xe2\x80\x9d\nFarlinger added, \xe2\x80\x9cThis Agreement reduces Assure\xe2\x80\x99s risk, minimizes complexity and accelerates payment on cases associated with Aetna Colorado.
  • Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission\xe2\x80\x99s Gold Seal of Approval\xc2\xae.

Assure Holdings Appoints John Flood to Board of Directors

Retrieved on: 
Wednesday, April 21, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Branches of biology

b'DENVER, April 21, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (\xe2\x80\x9cIONM\xe2\x80\x9d), has appointed John Flood to its board of directors.\nFlood brings thirty-five years of capital markets experience, as well as extensive operations, business building and governance expertise to Assure\xe2\x80\x99s board.

Key Points: 
  • b'DENVER, April 21, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (\xe2\x80\x9cIONM\xe2\x80\x9d), has appointed John Flood to its board of directors.\nFlood brings thirty-five years of capital markets experience, as well as extensive operations, business building and governance expertise to Assure\xe2\x80\x99s board.
  • At Craig-Hallum, Flood led the investment banking and institutional equity sales teams.
  • \xe2\x80\x9cHis strengths will complement the skills of our other directors, and John\xe2\x80\x99s perspective will prove invaluable as we continue to build our business and create shareholder value.
  • We are pleased to strengthen our board as Assure prepares for the next level of growth and profitability.\xe2\x80\x9d\nCommenting on his appointment, Flood said, \xe2\x80\x9cI am excited to join Assure\xe2\x80\x99s board of directors and help the Company navigate the rapidly evolving IONM industry from a strong competitive position.

EDGe Surgical Granted U.S. Patent for Next-Generation Awl-in-One Tap™

Retrieved on: 
Thursday, April 22, 2021
General Health, Surgery, Medical devices, Hospitals, Health, Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Branches of biology

b'EDGe Surgical, Inc. , a company focused on developing and manufacturing smart orthopedic and spine surgical instruments, announced today that its next-generation Awl-in-One Tap\xe2\x84\xa2 device has been granted patent 10,912,483 titled \xe2\x80\x9cHandheld devices for use in medical procedures\xe2\x80\x9d by the United States Patent and Trademark Office.\nAwl-in-One Tap is a single-use spinal surgery instrument with disposable neuromonitoring EMG system and digital depth measurement built in.

Key Points: 
  • b'EDGe Surgical, Inc. , a company focused on developing and manufacturing smart orthopedic and spine surgical instruments, announced today that its next-generation Awl-in-One Tap\xe2\x84\xa2 device has been granted patent 10,912,483 titled \xe2\x80\x9cHandheld devices for use in medical procedures\xe2\x80\x9d by the United States Patent and Trademark Office.\nAwl-in-One Tap is a single-use spinal surgery instrument with disposable neuromonitoring EMG system and digital depth measurement built in.
  • These claims provide broad protection for EDGe Surgical\xe2\x80\x99s next-generation version of its Awl-in-One Tap\xe2\x80\x99s NerveNAV\xe2\x84\xa2 technology.
  • EDGe Surgical now holds 17 U.S. patents and 11 patents outside the U.S. on this technology, with six additional patent applications pending in the U.S. and 13 outside the U.S.\nFor more information on EDGe Surgical and its products, visit www.edgesurgical.com and follow the company on LinkedIn and YouTube .\nEDGe Surgical, Inc. is a privately held medical device company committed to enhancing excellence in orthopedic and spine surgery instrumentation.
  • Driven by the goals of increasing accuracy, mitigating infection risk, and reducing cost, EDGe Surgical is setting a new industry standard.

New Mexico's Gallup-McKinley County Schools Commits to Major Social-Emotional Robotics & Curriculum Program

Retrieved on: 
Thursday, April 22, 2021
Branches of biology, Electroencephalography, Neurotechnology, Electrophysiology, Neurophysiology, Electrodiagnosis, Quantitative electroencephalography, Brain

"Thousands of students, led by their teachers, can now more effectively master social-emotional skills and meet IEP goals.

Key Points: 
  • "Thousands of students, led by their teachers, can now more effectively master social-emotional skills and meet IEP goals.
  • "\nMany research initiatives already leveraged the program to better understand the impact of assistive technology and evidence-based curriculum goal progression.\nIn one example , Dr. Shelley Margow used Quantitative Electroencephalo-graph (QEEG) to map the cognitive function of her patients\' brain waves before and after working with [the program].
  • She stated, "After three months of working with Milo, my students\' mental maps showed a huge change in how their brains received and processed information.
  • This correlated with the changes in the ASD learner\'s overall behavior.

Cardiac Insight Reports Increased Cardea 20/20 ECG™ Sales to Screen Young Athletes for Conditions at Risk for Sudden Cardiac Arrest

Retrieved on: 
Monday, April 5, 2021
Health, Medical devices, Cardiology, Medicine, Clinical medicine, Branches of biology, Electrodiagnosis, Cardiac electrophysiology, Medical tests, Cardiology, Electrocardiography, Electrophysiology, Wireless ambulatory ECG

Cardea 20/20 ECG enables physicians to quickly identify difficult-to-diagnose cardiac abnormalities, such as those associated with increased risks of sudden cardiac arrest (SCA) in active youth and athletes, using a 16-second noninvasive test.

Key Points: 
  • Cardea 20/20 ECG enables physicians to quickly identify difficult-to-diagnose cardiac abnormalities, such as those associated with increased risks of sudden cardiac arrest (SCA) in active youth and athletes, using a 16-second noninvasive test.
  • The Cardea 20/20 ECG System was designed specifically to detect cardiac risk conditions in active young adults.
  • Cardiac Insights 20/20 ECG Systems are an integral part of our comprehensive and growing ECG screening program initiative.
  • The companys products include the Cardea SOLO wearable ECG Sensor and Software Analysis System, and the Cardea 20/20 ECG the only resting ECG System designed for cardiac risk screening in young athletes at all levels of play.

Elite Education Group International Limited Announces Pricing of $6 Million Firm Commitment Initial Public Offering

Retrieved on: 
Thursday, March 25, 2021
Branches of biology, Brain–computer interfacing, Electrodiagnosis, Electroencephalography, Electrophysiology, Neurotechnology

MIDDLETOWN, Ohio, March 25, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq: EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced the pricing of its firm commitment initial public offering of 750,000units at an offering price of $8.00 per unit for total gross proceeds of $6.0 million.

Key Points: 
  • MIDDLETOWN, Ohio, March 25, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq: EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced the pricing of its firm commitment initial public offering of 750,000units at an offering price of $8.00 per unit for total gross proceeds of $6.0 million.
  • Each unit will immediately separate into one common share, one Series A warrant, and one Series B warrant.
  • The net proceeds to EEG from the sale of the securities are expected to be approximately $4.3 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • Elite Education Group International Limited, through its subsidiary Quest Holding International LLC, provides comprehensive, one-stop education solutions for Chinese students who are interested in study abroad programs in the US and other countries.

B-Secur Delivers Powerful ECG Algorithms and Analytics with Maxim Integrated’s Electrocardiogram Biometric Sensor Hub to Speed Time to Market

Retrieved on: 
Thursday, March 25, 2021
Hardware, FDA, Semiconductor, Manufacturing, Other Health, Technology, Medical devices, Other Technology, Cardiology, Biotechnology, Software, Health, Mobile, Wireless, Engineering, Medical Supplies, Medicine, Branches of biology, Human–computer interaction, Wearable devices, Cardiac electrophysiology, Electrocardiography, Electrodiagnosis, Electrophysiology, Science and technology in the Netherlands, Wearable technology, Sensor hub, B-Secur, Maxim Integrated

The MAX32663A electrocardiogram (ECG) biometric sensor hub is a Maxim MAX32660 ultra-low power microcontroller loaded with B-Securs HeartKey algorithms, which provides seamless communication with Maxims MAX30003 low power ECG sensor.

Key Points: 
  • The MAX32663A electrocardiogram (ECG) biometric sensor hub is a Maxim MAX32660 ultra-low power microcontroller loaded with B-Securs HeartKey algorithms, which provides seamless communication with Maxims MAX30003 low power ECG sensor.
  • The complete solution simplifies design and eliminates the burden of algorithm licensing to speed time to market.
  • The MAX32663A ECG biometric sensor hub and MAX30003 low power ECG sensor provide design engineers with a tiny, proven, quick path to integrate powerful ECG analysis features into their next wearable device.
  • The MAX32663A ECG biometric sensor hub and its evaluation board ( MAX30003WING2 ) are available now at Maxim Integrateds website and through authorized distributors.